As a dual agonist of both glucagon and GLP-1 receptors, Oxm has been shown to be a promising pharmacological agent in the treatment of obesity as it suppresses food intake and increases energy expenditure in both rodents and humans19–22. Here, GCG is linked to obesity disorder.